Value
8.8/10data confidence 60%| Component | Sub-score |
|---|---|
| P/E | 9.9 |
| P/S | 7.8 |
| EV/EBITDA | 8.7 |
- ▸Attractively valued
ABUS · Why this verdict
Why Arbutus Biopharma (ABUS) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.3/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Arbutus screens as attractively valued with very high reported returns, but those profits come from a one-off lumpy revenue quarter, short interest is 38%, and the price is only 10.3% below the analyst target, leaving little margin in a speculative biotech.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Headline profitability is driven by a single lump-sum quarter: March 2026 revenue was $179.1M versus about $1.0M in the June 2026 quarter, so ROE of 90% and 84% margins are not recurring. Revenue quarters | Recurring quarterly revenue rises well above the roughly $1.4M next-quarter estimate, or further licensing payments land. | ↓Deteriorating |
| CounterEarnings quality shows a red flag of -52% FCF to net income and Rule of 40 at -135, so reported margins likely overstate cash economics. | ||
Short interest of 38% with a put/call ratio of 2.17 and implied volatility of 188% makes price action extremely volatile and squeeze-prone. Risk breakdown | Short interest declines below 25% as sentiment improves, or a squeeze lifts the price toward the $4.63 target. | ↑Improving |
| CounterHeavy short positioning and put demand reflect informed pessimism, and a squeeze is not a reliable thesis. | ||
Baseline revenue is tiny (about $1.0M in the June 2026 quarter) and tied to a concentration risk in Moderna as counterparty. Bear case | Quarterly revenue stays above $1M, supported by the Moderna relationship, with earnings in 23 days. | ↑Improving |
| CounterA single counterparty dispute or royalty change would remove most recurring revenue, and the company has had officer changes. | ||
The shares are attractively valued on P/E, but at $4.20 they are only 10.3% below the $4.63 analyst target, with reward-to-risk of just 1.37. Analyst target | The analyst target rises above $5.50, widening upside as the pipeline progresses. | →Stable |
| CounterWith 7.5% downside to support versus 10.3% upside, the setup offers little compensation for binary biotech risk. | ||
Momentum is weak at 3.1/10, with price below the 200-day average and a flat slope, and institutions reducing holdings. Momentum breakdown | Momentum score recovers above 4.5/10 as price reclaims the 200-day average. | ↑Improving |
| CounterPositive news sentiment (+0.65) and a short squeeze setup could reverse the trend quickly. | ||
Headline profitability is driven by a single lump-sum quarter: March 2026 revenue was $179.1M versus about $1.0M in the June 2026 quarter, so ROE of 90% and 84% margins are not recurring.
↓DeterioratingRevenue quarters
- Expectation
- Recurring quarterly revenue rises well above the roughly $1.4M next-quarter estimate, or further licensing payments land.
CounterEarnings quality shows a red flag of -52% FCF to net income and Rule of 40 at -135, so reported margins likely overstate cash economics.
Short interest of 38% with a put/call ratio of 2.17 and implied volatility of 188% makes price action extremely volatile and squeeze-prone.
↑ImprovingRisk breakdown
- Expectation
- Short interest declines below 25% as sentiment improves, or a squeeze lifts the price toward the $4.63 target.
CounterHeavy short positioning and put demand reflect informed pessimism, and a squeeze is not a reliable thesis.
Baseline revenue is tiny (about $1.0M in the June 2026 quarter) and tied to a concentration risk in Moderna as counterparty.
↑ImprovingBear case
- Expectation
- Quarterly revenue stays above $1M, supported by the Moderna relationship, with earnings in 23 days.
CounterA single counterparty dispute or royalty change would remove most recurring revenue, and the company has had officer changes.
The shares are attractively valued on P/E, but at $4.20 they are only 10.3% below the $4.63 analyst target, with reward-to-risk of just 1.37.
→StableAnalyst target
- Expectation
- The analyst target rises above $5.50, widening upside as the pipeline progresses.
CounterWith 7.5% downside to support versus 10.3% upside, the setup offers little compensation for binary biotech risk.
Momentum is weak at 3.1/10, with price below the 200-day average and a flat slope, and institutions reducing holdings.
↑ImprovingMomentum breakdown
- Expectation
- Momentum score recovers above 4.5/10 as price reclaims the 200-day average.
CounterPositive news sentiment (+0.65) and a short squeeze setup could reverse the trend quickly.
Per-dimension breakdown
Quality
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 90%
- ▸Strong margins: 84%
- ▸Earnings quality RED FLAG: -52% FCF/NI
- ▸Rule of 40: -135 (fail)
Growth
5.0/10data confidence 50%Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.6 |
| OBV | 10.0 |
| MA position | 4.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 5.0 |
| Price target | 8.3 |
- ▸LLM news sentiment: +0.70 (n=2)
- ▸Analyst upside: 26%
Insider
3.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 2.4 |
| notable moves | 3.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions reducing
Peer rank
6.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.2 |
| quality rank | 9.7 |
| growth rank | 0.3 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.5 |
| support resistance | 6.4 |
| 52w position | 5.9 |
| gap | 6.0 |
Risk (lower is worse)
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 10.0 |
| days to cover | 7.5 |
| volatility | 5.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 8.4 |
| debt equity | 9.9 |
| news risk | 5.0 |
- ▸Short squeeze setup: 28% short, quality 7.5
- ▸High IV: 297%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| surprise avg | 10.0 |
| news activity | 6.0 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (5)
- MOMENTUM:5.1>=4.5
- INSIDER:OK
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (2)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.17
Upside
+7.3%
Downside
6.3%
Sizing output
AVOID
SetupRange Bound — RSI 59 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.1>=4.5. Top dim: Value at 8.8; weakest: Insider at 3.5. No conviction either direction.
The strongest dimensions are Value at 8.8, Sentiment at 7.1, and Risk (lower is worse) at 7.0; the weakest are Insider at 3.5, Growth at 5.0, and Momentum at 5.1. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.17 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Lumpy One Off Profitability
Trip ifQuarterly revenue exceeds $20M in 2 consecutive quarters.
- P2High Short Interest Volatility
Trip ifShort interest falls below 20% from the current 38%.
- P3Moderna Counterparty Dependence
Trip ifQuarterly revenue falls below $500K for 2 consecutive quarters.
- P4Limited Upside To Target
Trip ifAnalyst target rises above $5.50 from the current $4.63.
- P5Weak Price Momentum
Trip ifMomentum score rises above 4.5/10 from the current 3.1.